Table 5.
Plasma markers of bacterial translocation and inflammation/infection at (a) baseline, (b) day 5 of trial and (c) day 10 of trial.
| (a) | |||
|---|---|---|---|
| Plasma marker of infection/inflammation Baseline |
PPI at baseline (oral and IV) Median (95% CI) (numbers of patients) | Non-PPI at baseline Median (95% CI) (numbers of patients) |
P value |
| Interleukin 1-βeta (IL- 1β pg/ml) | 0 (0–1) (62) | 0 (0-0) (51) | 0.28 |
| Interleukin-6 (IL-6 pg/ml) | 13 (8.8–19.8) (62) | 12.6 (10.3–18.1) (51) | 0.90 |
| Interleukin-10 (IL-10 pg/ml) | 0 (0–0.3) (62) | 0 (0-0) (51) | 0.84 |
| Tumour necrosis factor alpha (TNF-α pg/ml) | 4 (3.2–5) (62) | 4.2 (3.1–5) (51) | 0.64 |
| Interleukin-4 (IL-4 pg/ml) | 0 (0-0) (62) | 0 (0-0) (51) | 0.73 |
| Interleukin-8 (IL-8 pg/ml) | 115.2 (45.8–155.9) (62) | 76 (38.2–154.3) (51) | 0.88 |
| Procalcitonin (PCT ng/ml) | 158.9 (124.6–279.2) (62) | 128.8 (93.8–214.5) (51) | 0.65 |
| Lipopolysaccharide binding protein (LBP ng/ml) | 1895 (1450–3010) (63) | 1780 (1330–3400) (51) | 0.50 |
| Soluble CD 14 (sCD14 ng/ml) | 3075 (1570–7520) (63) | 2230 (1410–3870) (51) | 0.71 |
| CD163 (ng/ml) | 2221 (1758–2872) (63) | 2746 (2527–3281) (49) | 0.18 |
| Chemokine ligand 8/monocyte chemoattractant protein 2 (CCL8/MCP-2 pg/ml) | 53.5 (47.4–63.1) (62) | 46.5 (39–54) (49) | 0.22 |
| Prostaglandin E2 (PGE2, pg/ml) | 647.9 (550–993) (62) | 742.8 (537–936) (50) | 0.97 |
| (b) | |||
|---|---|---|---|
| Plasma marker of infection/inflammation Day 5 |
PPI at baseline (oral and IV) Median (95% CI) (numbers of patients) | Non-PPI at baseline Median (95% CI) (numbers of patients) |
P value |
| IL1-β (pg/ml) | 0 (0–1.3) (46) | 0 (0-0) (42) | 0.27 |
| IL-6 (pg/ml) | 10.1 (8–12.9) (46) | 9.8 (6.2–14) (42) | 0.82 |
| IL-10 (pg/ml) | 0 (0-0) (46) | 0 (0-0) (42) | 0.70 |
| TNF-α (pg/ml) | 3.8 (2.7) (46) | 4.15 (3.1–5.2) (42) | 0.61 |
| IL-4 (pg/ml) | 0 (0-0) (46) | 0 (0-0) (42) | 0.47 |
| IL-8 (pg/ml) | 39.8 (20–91.8) (46) | 45 (23.3–93.1) (42) | 0.98 |
| PCT (ng/ml) | 110.4 (66.4–231.2) (46) | 226.5 (69.8–284.4) (42) | 0.32 |
| LBP (ng/ml) | 1540 (1190–1930) (49) | 1645 (1330–2250) (44) | 0.41 |
| sCD14 (ng/ml) | 5210 (1980–7370) (49) | 2310 (1440–7820) (44) | 0.59 |
| CD163 (ng/ml) | 2153 (18189–2731) (46) | 2853 (2382–3290) (41) | 0.06 |
| CCL8/MCP-2 (pg/ml) | 56.1 (41.4–65) (46) | 45.5 (39.1–53.8) (41) | 0.22 |
| (c) | |||
|---|---|---|---|
| Plasma marker of infection/inflammation Day 10 |
PPI at baseline (oral and IV) Median (95% CI) (n = 14) |
Non-PPI at baseline Median (95% CI) (n = 13) |
P value |
| IL1-β (pg/ml) | 0 (0–0.2) | 0 (0–0) | 0.62 |
| IL-6 (pg/ml) | 10.75 (4.2–24) | 11 (7.2–24.5) | 0.79 |
| IL-10 (pg/ml) | 0 (0–3) | 0 (0–0) | 0.20 |
| TNF-α (pg/ml) | 2.9 (1.7–4.9) | 3.7 (0.7–6.2) | 0.90 |
| IL-4 (pg/ml) | 0 (0–4) | 0 (0–5.8) | 0.36 |
| IL-8 (pg/ml) | 42.15 (16.6–321.2) | 20 (9.8–203.1) | 0.46 |
| PCT (ng/ml) | 118 (40.5–287.3) | 107.8 (48.9–211.4) | 0.65 |
| LBP (ng/ml) | 3205 (1170–9010) | 6070 (1180–6910) | 0.55 |
| sCD14 (ng/ml) | 1007 (624–7100) | 1200 (817–2410) | 0.72 |
| CD163 (ng/ml) | 2391 (1224–3780) | 2761 (867–4274) | 0.94 |
| CCL8/MCP-2 (pg/ml) | 38.2 (20.7–59.5) | 45.3 (22.1–72.8) | 0.59 |
| PGE2 (pg/ml) | 680.3 (353–1275) | 904.3 (392–2655) | 0.51 |